期刊文献+

肿瘤物理微环境介导肿瘤耐药性研究进展 被引量:4

Progress in the research on tumor drug-resistance mediated by cancer physical microenvironment
原文传递
导出
摘要 肿瘤耐药性一般认为是因基因突变、扩增或表观遗传改变影响肿瘤细胞药物摄取、代谢或外排造成。肿瘤物理微环境不但影响药物在肿瘤组织中的分布,而且肿瘤微环境自身异质.陛还将造成肿瘤细胞增殖速度差异和低氧及酸中毒,并影响肿瘤的耐药性。就肿瘤物理微环境特点出发,综述了其与肿瘤耐药性之间的关系,并探讨和展望了通过改善肿瘤物理微环境来提高肿瘤化疗灵敏性的策略及未来的研究方向。 Anticancer drugs resistance is often ascribed to gene mutation, amplification or epigenetic changes that affect the uptake, metabolism or export of drugs at the cell level. Tumor physical microenvironment not only influences the drug distribution but also causes difference in cell proliferation rate and hypoxia or acidosis due to its heterogeneity, which could affect the tumor drug resistance. This review discusses the relationship between cancer physical microenvironment and drug resistance and the strategies for enhancement of the chemotherapy sensitivity through modification of the tumor physical microenvironments, as well as foreground of the research.
作者 李华根 李远
出处 《国际生物医学工程杂志》 CAS 2012年第1期53-56,共4页 International Journal of Biomedical Engineering
基金 基金项目:重庆医科大学附属永川医院院级课题项目(YJQN2011027) 重庆永川区2011年科技支撑“健康永川”专项基金项目(YCSTC,2011BF5001)
关键词 肿瘤 物理微环境 耐药 Cancer Physical microenvironment Drug resistance
  • 相关文献

参考文献33

  • 1Tefl WA, Mansell SE, Kim RB. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (muhidrug resistance 1)[J]. Drug Metab Dispos, 2011, 39 (3): 558- 562.
  • 2Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment[J]. J Natl Cancer Inst, 2007, 99(19): 1441-1454.
  • 3Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology[J]. Semin Radiat Oncol, 2004, 14(3): 198-206.
  • 4Di Paolo A, Bocci G. Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification[J]. Curr Oncol Rep, 2007, 9(2): 109-114.
  • 5Stohrer M, Boucher Y, Stangassinger M, et al. Oncotic pressure in solid tumors is elevated[J]. Cancer Res, 2000, 60(15): 4251-4255.
  • 6Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure- an obstacle in cancer therapy[J]. Nat Rev Cancer, 2004, 4(10): 806- 813.
  • 7Curti BD, Urba WJ, Alvord WG, et al. Interstitial pressure of subcu- taneous nodules in melanoma and lymphoma patients: changes dur- ing treatment[J]. Cancer Res, 1993, 53(10 Suppl): 2204-2207.
  • 8Herrera FG, Chan P, Doll C, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor mieroenviron- ment[J]. Int J Radiat Oncol Biol Phys, 2007, 67(1): 97-103.
  • 9Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix as- sembly in interstitial transport in solid tumors[J]. Cancer Res, 2000, 60(9): 2497-2503.
  • 10Grantab R, Sivananthan S, Tannoek IF. The penetration of anticaneer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells[J]. Cancer Res, 2006, 66(2): 1033-1039.

共引文献3

同被引文献50

  • 1Bysell H, Mansson R, Hansson P, et al. Microgels and microcapsules in peptide and protein drug delivery[J]. Adv Drug Deliv Rev, 201 l, 63(13): 1172-1185.
  • 2Wu Jue-heng, Jiang Yi, Yang Wan, et al. Dual function of RGD- modified VEGI-192 for breast cancer treatment[J]. Bioconjug Chem, 2012, 23(4): 796-804.
  • 3Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems[J]. Colloids Surf B Biointerfaces, 2010, 75(1): 1-18.
  • 4Atkinson J. Can the inhibition of TAFI affect kidney plasmin activity, ECM accumulation and the progression of experimental chronic kidney disease?[D]. Sheffield: The University of Sheffield, 2013.
  • 5Vincent T, Mechti N. Extracellular matrix in bone marrow can mediate drug resistance in myeloma[J]. Leuk Lymphoma, 2005, 46 (6): 803-811.
  • 6Kong HI, Mooney DJ. Mieroenvironmental regulation of biomacro- molecular therapies[J]. Nat Rev Drug Discov, 2007, 6(6): 455-463.
  • 7Arnold M, Cavalcanti-Adam EA, Glass R, et al. Activation of integrin function by nanopatterned adhesive interfaces[J]. Chemphysehem, 2004, 5(3): 383-388.
  • 8Guilak F, Cohen DM, Estes BT, et al. Control of stern cell fate byphysical interactions with the extracellular matrix[J]. Cell Stem Cell, 2009, 5(1): 17-26.
  • 9Duvall CL, Convertine AJ, Benoit DS, et al. Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer[J]. Mol Pharm, 2010, 7(2): 468-476.
  • 10Flynn CR, Cheung-Flynn J, Smoke CC, et al. Internalization and intracellular trafficking of a PTD-eonjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts[J]. J Pharm Sci, 2010, 99(7): 3100-3121.

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部